Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$92.88

1.32 (1.44%)

19:00
11/10/19
11/10
19:00
11/10/19
19:00

Piper Jaffray reiterates Overweight on Alnylam after data presentation

Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $145 price target on Alnylam after the company initiated its Phase III ILLUMINATE-C trial of lumasirin in primary hyperoxaluria type 1 patients with advanced renal disease and presented Phase II open-label extension data showing "lumasirin reduced urinary oxalate excretion 76% from Phase I/II baseline levels." Tenthoff said that Alnylam will report Phase III ILLUMINATE-A data on lumasiran by the end of the year. The analyst forecast 2019 Onpattro sales of $160M that will grow to $330M in 2020, and noted that Onpattro and nextgen vutrisiran are being evaluated in Phase III cardiomyopathy trials that could expand the Onpattro label by 2021/'22. Tenthoff added that he is confident in givosiran getting FDA approval, and noted its has a PDUFA date of February 4 with no expected AdComm.

  • 13

    Nov

  • 18

    Nov

  • 07

    Dec

  • 04

    Feb

ALNY Alnylam
$92.88

1.32 (1.44%)

09/02/19
PIPR
09/02/19
NO CHANGE
Target $145
PIPR
Overweight
Alnylam price target raised to $145 from $142 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam (ALNY) to $145 from $142 after partner The Medicine Co. (MDCO) presented positive Phase III ORION-11 data on inclisiran in 1,617 ASCVD patients at the European Society of Cardiology Congress in Paris. The analyst remains confident in inclisiran approval next year and Alnylam is eligible for milestones plus up to double-digit royalties. He reiterates an Overweight rating on Alnylam shares.
09/03/19
STFL
09/03/19
NO CHANGE
Target $116
STFL
Buy
Alnylam data broadly support inclisiran as approvable drug, says Stifel
After Alnylam (ALNY) partner The Medicine Co. (MDCO) presented Phase 3 data on inclisiran at the European Society of Cardiology Congress, Stifel analyst Paul Matteis said the efficacy data were positive, but the focus is really on safety and "encouragingly" the adverse events, incidence of death, and serious adverse events all occurred at similar rates on inclisiran versus placebo. The analyst, who believes the data broadly support inclisiran as an approvable drug, also thinks the results validate Alnylam's recent efforts in non-orphan areas. Matteis, who noted that Alnylam will receive up to a 20% royalty on inclisiran sales, has a Buy rating and $116 price target on Alnylam shares.
09/10/19
PIPR
09/10/19
NO CHANGE
Target $145
PIPR
Overweight
Alnylam's updated OLE data shows reduced 'daily worst pain,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $145 price target on Alnylam after the company presented new results from the Phase III ENVISION trial and Phase I/II OLE study of givosiran in Acute Hepatic Poprphyria at the International Congress on Porphyrins and Porphyrias Conference. Tenthoff says the updated OLE data showed that monthly givosiran dosing reduced median annualized attack rate to 0.22 over 30 months, and patient reported outcomes also revealed reduced "daily worst pain" for subjects receiving givosiran, lower use of opioids and improved quality of life. Tenthoff tells investors in a research note that he is "confident" in FDA approval by the February 4 PDUFA date.
11/01/19
RAJA
11/01/19
UPGRADE
Target $24
RAJA
Outperform
Intellia Therapeutics upgraded to Outperform at Raymond James
Raymond James analyst Steven Seedhouse upgraded Intellia Therapeutics to Outperform from Market Perform with a $24 price target. In a research note to investors, Seedhouse says Intellia's NTLA-2001 is poised to benefit from the "heavy lifting" Pfizer (PFE) is doing commercially with Vyndaqel in ATTR-cardiomyopathy, adding that Intellia is also advancing manufacturing related activities in support of a Phase 1 trial for engineered cell program WT1-TCR in AML. The analyst also says Intellia's lead gene editing program, NTLA-2001 has "really good" primate data showing TTR knockdown potentially better than Alnylam's (ALNY) patisiran. He expects the market will already start to impute downstream clinical benefit for NTLA-2001 after only a few patients with initial TTR knockdown data, because of the collective data for Ionis Pharmaceuticals' (IONS) inotersen and Alnylam's patisiran showing knockdown is relevant.

TODAY'S FREE FLY STORIES

NFLX

Netflix

$310.48

-1.4 (-0.45%)

, DIS

Disney

$148.25

1.34 (0.91%)

18:09
11/22/19
11/22
18:09
11/22/19
18:09
Periodicals
Netflix internal data shows company not hurt by Disney+, Bloomberg says »

Netflix's (NFLX)…

NFLX

Netflix

$310.48

-1.4 (-0.45%)

DIS

Disney

$148.25

1.34 (0.91%)

AAPL

Apple

$261.81

-0.23 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

TMUS

T-Mobile

$78.59

0.89 (1.15%)

18:08
11/22/19
11/22
18:08
11/22/19
18:08
Periodicals
T-Mobile says some customers affected by data breach, Bloomberg reports »

T-Mobile said that hacker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 09

    Dec

WVE

Wave Life Sciences

$30.43

0.2 (0.66%)

18:05
11/22/19
11/22
18:05
11/22/19
18:05
Hot Stocks
Wave Life Sciences director Verdine sells 30K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$371.18

4.71 (1.29%)

17:42
11/22/19
11/22
17:42
11/22/19
17:42
Periodicals
Canada agency: Official's email on 737 reflects working-level view, Reuters says »

Canadian regulator…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CACI

CACI

$231.32

-4.2 (-1.78%)

17:36
11/22/19
11/22
17:36
11/22/19
17:36
Hot Stocks
CACI awarded $112.53M Army contract modification »

CACI was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

AGO

Assured Guaranty

$48.65

-0.03 (-0.06%)

17:35
11/22/19
11/22
17:35
11/22/19
17:35
Hot Stocks
Assured Guaranty CIO buys 25.5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$310.48

-1.4 (-0.45%)

, DIS

Disney

$148.25

1.34 (0.91%)

17:33
11/22/19
11/22
17:33
11/22/19
17:33
Periodicals
Netflix internal data shows company not hurt by Disney+, Bloomberg says »

Netflix's (NFLX)…

NFLX

Netflix

$310.48

-1.4 (-0.45%)

DIS

Disney

$148.25

1.34 (0.91%)

AAPL

Apple

$261.81

-0.23 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

OYST

Oyster Point Pharma

$14.84

0.64 (4.51%)

17:24
11/22/19
11/22
17:24
11/22/19
17:24
Hot Stocks
Oyster Point Pharma discloses 'positive' Phase 1 results for OC-01 nasal spray »

Oyster Point Pharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SACH

Sachem Capital

$4.21

(0.00%)

17:19
11/22/19
11/22
17:19
11/22/19
17:19
Hot Stocks
Sachem Capital co-CEO Villano steps down »

Sachem Capital announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

$57.63

-0.61 (-1.05%)

17:18
11/22/19
11/22
17:18
11/22/19
17:18
Hot Stocks
Intel board member Goetz buys $5.04M in stock »

Intel board member James…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 09

    Dec

  • 23

    Jan

SWAV

ShockWave Medical

$38.00

0.18 (0.48%)

17:12
11/22/19
11/22
17:12
11/22/19
17:12
Hot Stocks
ShockWave Medical CEO sells 30K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAEX

SAExploration

$2.61

0.16 (6.53%)

17:01
11/22/19
11/22
17:01
11/22/19
17:01
Hot Stocks
SAExploration receives Nasdaq non-compliance letter »

SAExploration Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OFG

OFG Bancorp

$20.48

0.17 (0.84%)

17:00
11/22/19
11/22
17:00
11/22/19
17:00
Hot Stocks
OFG Bancorp buys 40K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MO

Altria Group

$49.00

0.17 (0.35%)

, BTI

British American Tobacco

$38.15

-0.21 (-0.55%)

16:47
11/22/19
11/22
16:47
11/22/19
16:47
Periodicals
POTUS in favor of raising minimum vaping age to 21, MarketWatch says »

U.S. President Donald…

MO

Altria Group

$49.00

0.17 (0.35%)

BTI

British American Tobacco

$38.15

-0.21 (-0.55%)

IMBBY

Imperial Brands

$0.00

(0.00%)

PM

Philip Morris

$82.39

-1.08 (-1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

HIBB

Hibbett Sports

$28.64

3.57 (14.24%)

16:45
11/22/19
11/22
16:45
11/22/19
16:45
Recommendations
Hibbett Sports analyst commentary at Baird »

Hibbett Sports price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

MSCI

MSCI

$257.97

2.295 (0.90%)

16:43
11/22/19
11/22
16:43
11/22/19
16:43
Hot Stocks
MSCI COO sells 6,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$39.53

0.54 (1.39%)

, VIA

Viacom

$26.06

-0.03 (-0.11%)

16:35
11/22/19
11/22
16:35
11/22/19
16:35
Hot Stocks
CBS to list ViacomCBS shares on Nasdaq following merger »

CBS Corporation (CBS)…

CBS

CBS

$39.53

0.54 (1.39%)

VIA

Viacom

$26.06

-0.03 (-0.11%)

VIAB

Viacom

$23.64

0.38 (1.63%)

ICE

IntercontinentalExchange

$93.70

-0.19 (-0.20%)

NDAQ

Nasdaq

$104.36

-0.31 (-0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DIS

Disney

$148.25

1.34 (0.91%)

16:32
11/22/19
11/22
16:32
11/22/19
16:32
Periodicals
Disney sees 'Frozen 2' having possible $40M opening day, Bloomberg says »

Disney told Bloomberg it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCRH

Blue Capital

$7.00

(0.00%)

16:31
11/22/19
11/22
16:31
11/22/19
16:31
Hot Stocks
Blue Capital declares special distribution of 57c per common share »

Blue Capital Reinsurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
11/22/19
11/22
16:30
11/22/19
16:30
Options
Preliminary option volume of 18.4M today »

Preliminary option volume…

STX

Seagate

$59.27

-0.21 (-0.35%)

16:24
11/22/19
11/22
16:24
11/22/19
16:24
Hot Stocks
Seagate chairman sells 90K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEL

American Equity

$29.12

0.155 (0.54%)

16:21
11/22/19
11/22
16:21
11/22/19
16:21
Hot Stocks
American Equity raises annual dividend 7% to 30c per share »

American Equity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
11/22/19
11/22
16:20
11/22/19
16:20
Options
Closing CBOE SPX and VIX Index summary for November 22nd »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MS

Morgan Stanley

$49.25

0.4 (0.82%)

16:18
11/22/19
11/22
16:18
11/22/19
16:18
Hot Stocks
Morgan Stanley's Rooney sells over 50,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 06

    Dec

TSLA

Tesla

$332.91

-21.91 (-6.18%)

, GPS

Gap

$16.92

0.7 (4.32%)

16:17
11/22/19
11/22
16:17
11/22/19
16:17
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks ended the session…

TSLA

Tesla

$332.91

-21.91 (-6.18%)

GPS

Gap

$16.92

0.7 (4.32%)

UBER

Uber

$29.57

0.11 (0.37%)

CVX

Chevron

$118.62

-0.18 (-0.15%)

LB

L Brands

$18.01

0.83 (4.83%)

JWN

Nordstrom

$37.96

3.67 (10.70%)

SPLK

Splunk

$140.52

13.72 (10.82%)

PSTG

Pure Storage

$16.85

-2.99 (-15.07%)

FL

Foot Locker

$40.24

-1.22 (-2.94%)

WSM

Williams-Sonoma

$67.44

-1.325 (-1.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 05

    Dec

  • 09

    Dec

  • 12

    Dec

  • 27

    Feb

  • 10

    Mar

  • 11

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.